Rapid Molecular Diagnostics Enables Individualized Frontline Treatment of CBFA2T3::GLIS2-Rearranged Acute Myeloid Leukemia.
Fast genetic sequencing enabled two children with a rare aggressive leukemia to receive personalized therapy instead of standard chemotherapy.
This case series describes 2 pediatric patients with CBFA2T3::GLIS2-rearranged AML, a rare subtype with only 27% 5-year EFS, in whom Nanopore whole genome sequencing provided rapid molecular identification enabling individualized frontline treatment with azacitidine, venetoclax, and gemtuzumab rather than standard chemotherapy. The cases demonstrate a proof-of-concept for rapid genomic diagnostics driving personalized therapy selection in a pediatric AML subtype that represents a critical unmet need.
What the study was
- Study design
- Case series (2 patients)
- Population
- 2 pediatric patients with CBFA2T3::GLIS2-rearranged AML at UNC Chapel Hill; rare AML subtype with 27% 5-year EFS
- Sample size
- 2
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Pediatric Blood & Cancer
Why it surfaced
Proof-of-concept for Nanopore WGS-enabled precision treatment in a rare pediatric AML subtype with very poor prognosis; sparse-topic exception and rare-disease-signal exception applied for 2-patient case series under hematologic malignancies + rare disease watchlist overlap.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.